| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 09/12/2006 | US7105316 Neisseria lactoferrin binding protein |
| 09/12/2006 | US7105303 Antibodies to hepatitis C virus asialoglycoproteins |
| 09/12/2006 | US7105229 Dispersing a matrix of nanostructured liquid phase or a dehydrated variant and a nanostructured liquid crystalline phase or a dehydrated variant in nonlamellar material; cooling or evaporating a volatile solvent |
| 09/12/2006 | US7105171 Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia |
| 09/12/2006 | US7105170 comprises in vitro granuloma model containing fibroblasts for drug screening vaccines; kits |
| 09/12/2006 | US7105169 Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use |
| 09/12/2006 | US7105165 Mutant human hepatitis B viral strain and uses thereof |
| 09/12/2006 | US7105164 HIV-specific cytotoxic T-cell responses |
| 09/12/2006 | US7105163 Mite protein |
| 09/12/2006 | US7105162 Peptide or protein from a pathogenic or tumor agent having immunomodulatory activity with an adjuvant capable of increasing the binding of the peptide to the cells of the individual or increasing the entry of the peptide into the cells; strengthening immunomodulatory activity; polyamino acids adjuvants |
| 09/12/2006 | US7105161 Proteinaceous adjuvants |
| 09/12/2006 | US7105160 Antibody-serum protein hybrids |
| 09/12/2006 | US7105159 Purified monoclonal antibody which binds to a fragment of an outer membrane domain of prostate specific membrane antigen, PSM antigen antibodies conjugated to a radioisotope or a toxin;measuring the amount of PSM antigen in a biological sample |
| 09/12/2006 | US7105158 Methods of administering microencapsulated materials for immune modulated diseases |
| 09/12/2006 | US7105157 Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| 09/12/2006 | US7105149 Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/myeloma |
| 09/12/2006 | CA2236598C Treatment of cardiomyopathy by removal of autoantibodies |
| 09/12/2006 | CA2043932C Bacterin for the treatment of fusobacterium necrophorum diseases and a method for the production thereof |
| 09/08/2006 | WO2006094134A2 Kim-1 antibodies for treatment of th2-mediated conditions |
| 09/08/2006 | WO2006093794A1 Heterodimeric protein binding compositions |
| 09/08/2006 | WO2006093337A1 Preventive/therapeutic agent for cancer |
| 09/08/2006 | WO2006093071A1 ANTI-IDIOTYPE ANTIBODY HAVING ANTIFUNGAL ACTIVITY ON FUNGUS CARRYING β-GLUCAN SYNTHASE AND UTILIZATION OF THE SAME |
| 09/08/2006 | WO2006092607A1 Pharmaceutical composition |
| 09/08/2006 | WO2006092168A1 Pharmaceutical preparation that can be administered orally for treating fish, production method for said preparation and use of the latter |
| 09/08/2006 | WO2006092046A1 Hiv vaccine composition |
| 09/08/2006 | WO2006064373A3 Methods of purifying immunologlobulins |
| 09/08/2006 | WO2006055623A3 Method and compositions for prevention and treatment of malaria infections |
| 09/08/2006 | WO2006044205A3 Methods and compositions for needleless delivery of macromolecules |
| 09/08/2006 | WO2006041866A3 Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes |
| 09/08/2006 | WO2006040076A3 Vaccination adjuvants pam3cys, poly(i:c), imiquimod, loxoribine, r-848 and cpg-dna together with mhc i or mhc ii epitopes |
| 09/08/2006 | WO2006039652A3 Chondroitin sulfate a binding domains |
| 09/08/2006 | WO2006029891A3 Change of the load state of mhc molecules |
| 09/08/2006 | WO2006029224A3 Methods of using death receptor ligands and cd20 antibodies |
| 09/08/2006 | WO2006023211A3 Antigens targeted by pathogenic ai4 t cells in type 1 diabetes and uses thereof |
| 09/08/2006 | WO2006022682A3 Method and compositions for treating diseases targeting cd49b |
| 09/08/2006 | WO2006007366A3 SKIN IMMUNIZATION USING LT-STa FUSION PROTEINS |
| 09/08/2006 | WO2005091805A3 Methods and compositions for inhibition of metastasis |
| 09/08/2006 | WO2005089372A3 Therapeutic synergy of anti-cancer compounds |
| 09/08/2006 | WO2005051307A3 Epha2 agonistic monoclonal antibodies and methods of use thereof |
| 09/08/2006 | WO2005010035A3 Alternate reading frame polypeptides derived from hepatitis c and methods of their use |
| 09/08/2006 | WO2004053066A3 Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy |
| 09/08/2006 | CA2599967A1 Kim-1 antibodies for treatment of th2-mediated conditions |
| 09/08/2006 | CA2599875A1 Preventive/therapeutic agent for cancer |
| 09/08/2006 | CA2599831A1 Pharmaceutical preparation that can be administered orally for treating fish, production method for said preparation and use of the latter |
| 09/08/2006 | CA2599734A1 Humanized l243 antibodies |
| 09/08/2006 | CA2599329A1 Pharmaceutical composition |
| 09/08/2006 | CA2599265A1 Heterodimeric protein binding compositions |
| 09/08/2006 | CA2599017A1 Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| 09/08/2006 | CA2598833A1 Anti-angiogenic compounds |
| 09/08/2006 | CA2598567A1 Influenza virus harvester |
| 09/08/2006 | CA2597097A1 Treatment of bone disorders |
| 09/08/2006 | CA2573392A1 Methods of detecting a phenotype of a polymorphic protein |
| 09/07/2006 | US20060199947 Naturally-occurring variants of B7 proteins produced by alternative RNA splicing or alternative termination of full-length amino acid sequence; regulation of immune response in an animal; immunostimulants; anticarcinogenic agents, infections; antiallergens; antiinflammatory agents; veterinary medicine |
| 09/07/2006 | US20060199946 Apoptosis inducing agent and method for inducing apoptosis |
| 09/07/2006 | US20060199842 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
| 09/07/2006 | US20060199781 Assays based on BTF3 activity |
| 09/07/2006 | US20060199780 Methods for modulating T cell survival by modulating bcl-XL protein level |
| 09/07/2006 | US20060199778 Methods and products related to non-viral transfection |
| 09/07/2006 | US20060199777 Novel technology of intracellular delivery of dna oligonucleotides to improve drug activity |
| 09/07/2006 | US20060199228 Peptides for treatment of autoimmune diseases |
| 09/07/2006 | US20060199180 Compositions and methods relating to ovarian specific genes and proteins |
| 09/07/2006 | US20060199179 Method for diagnosis of colorectal tumors |
| 09/07/2006 | US20060199177 T helper cell epitopes |
| 09/07/2006 | US20060198882 Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer |
| 09/07/2006 | US20060198855 Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection |
| 09/07/2006 | US20060198854 Vector platforms derived from the alphavirus vaccines |
| 09/07/2006 | US20060198853 Papilloma virus capsomere vaccine formulations and methods of use |
| 09/07/2006 | US20060198852 Collagen-binding MSCRAMMs of Bacillus anthracis and uses therefor |
| 09/07/2006 | US20060198851 Humanized Abeta antibodies for use in improving cognition |
| 09/07/2006 | US20060198850 Pharmaceutical formulation and a method of making same |
| 09/07/2006 | US20060198849 Preparation method of igy for preventing and cure mouth disease and the toothpaste base on the igy |
| 09/07/2006 | US20060198848 Administering intravenously a composition comprising monomeric IgA, dimeric IgA, and IgG prepared from pooled human plasma, wherein monomeric and dimeric IgA comprise at least 35% to 55% of total immunoglobulins present in composition |
| 09/07/2006 | US20060198847 Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis |
| 09/07/2006 | US20060198846 Combinations for the treatment of diseases involving angiogenesis |
| 09/07/2006 | US20060198845 Monoclonal antibody against human hepatoma and use thereof |
| 09/07/2006 | US20060198844 Determining amount of the BMP-2/BMP-2 receptor complex in the formed in the presence of test agent;identifying a candidate agent for for use in reducing vascularization in non-small cell lung tumors if amount of complex formed in presence of test agent is lower than amount formed in absence of compound |
| 09/07/2006 | US20060198843 a cancer which expresses epidermal growth factor receptor; blocking ligand activation of a receptor; binding of monoclonal antibody 2C4 to ErbB2; chemotherapeutic agents are 5-fluorouracil leucovorin, levamisole |
| 09/07/2006 | US20060198842 treating skeletal muscle atrophy with a corticotropin releasing factor 2 receptor (CRF2R) agonist such as Sauvagine, urocortin II or an antibody |
| 09/07/2006 | US20060198841 Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
| 09/07/2006 | US20060198840 increased in vivo half-lives due to the presence of an immunoglobulin G (IgG) constant domain; pharmacokinetics; diagnosis or immunotherapy; antibody conjugates; palivizumab |
| 09/07/2006 | US20060198839 Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions |
| 09/07/2006 | US20060198831 Nitrosylation of protein SH groups and amino acid residues as a therapeutic modality |
| 09/07/2006 | US20060198820 Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
| 09/07/2006 | US20060198817 Materials and methods for preventing and treating microbe-mediated epithelial disorders |
| 09/07/2006 | US20060198784 Methods of treatment using antibodies to Neutrokine-alpha |
| 09/07/2006 | DE112004001863T5 Verfahren und Verwendung von Bindungskomponenten zur Verbesserung der Testspezifität The method and use of binding components to improve the specificity test |
| 09/07/2006 | DE102005010288A1 Pharmazeutisches, oral applizierbares Präparat zur Behandlung von Fischen, Herstellungsverfahren für dieses und seine Verwendung Pharmaceutical, orally applicable product for the treatment of fish, production method thereof and use thereof |
| 09/07/2006 | DE10015906B4 Gerichteter Gentransfer in Thy-1-positive Zellen Targeted gene transfer in Thy-1-positive cells |
| 09/06/2006 | EP1698701A1 Use of MHC class II ligands as adjuvant for vaccination and lag-3 in cancer treatment |
| 09/06/2006 | EP1698693A1 Royal jelly peptide and composition containing the same |
| 09/06/2006 | EP1698640A1 Method of stabilizing antibody and stabilized solution-type antibody preparation |
| 09/06/2006 | EP1698347A2 hiv-1 tat, or derivatives thereof for prophylactic and therapeutic vaccination |
| 09/06/2006 | EP1698345A2 Peptide antagonists of zonulin and methods for use of the same |
| 09/06/2006 | EP1697748A2 Methods for generating multimeric molecules |
| 09/06/2006 | EP1697521A2 Multi plasmid system for the production of influenza virus |
| 09/06/2006 | EP1697520A2 Fc polypeptides with novel fc ligand binding sites |
| 09/06/2006 | EP1697517A1 Brachyspira pilosicoli 72kda outer-membrane protein and diagnostic and therapeutic uses thereof |
| 09/06/2006 | EP1697511A2 Immunotherapy compositions, method of making and method of use thereof |
| 09/06/2006 | EP1697497A2 Liver cancer biomarkers |
| 09/06/2006 | EP1697421A2 Bispecific antibodies |